Abstract
The optimal choice of first-line systemic therapy in initially unresectable metastatic colorectal cancer is becoming increasingly complex. Treatment selection and intensity should consider several factors including molecular status, primary tumour location, disease sites and burden, performance status and, importantly, patient preference. Although doublet chemotherapy backbone (a fluoropyrimidine [fluorouracil or capecitabine] and oxaliplatin, or a fluoropyrimidine and irinotecan) is typically recommended for first-line therapy in patients with unresectable metastatic colorectal cancer, the role of both higher intensity triplet chemotherapy (fluorouracil, oxaliplatin, and irinotecan) and lower intensity single-agent fluoropyrimidine chemotherapy have been explored in selected patient populations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
